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Abstract
Hyperphosphatemia in the absence of renal failure is an unusual occurrence, particularly in children, but is a
common primary feature of familial hyperphosphatemic tumor calcinosis. We report a child with
hyperphosphatemia who presented with multiple episodes of neurologic dysfunction involving lower motor
neuron facial nerve palsy along with sequential visual loss. He also had an episode of stroke. There was an
extensive metastatic calcification of soft tissue and vasculature. Hyperphosphatemia with normal serum
alkaline phosphatase, calcium, parathyroid hormone, and renal function was noted. He was managed with
hemodialysis and sevelamer (3 months) without much success in reducing serum phosphate level, requiring
continuous ambulatory peritoneal dialysis (3 years). Intact fibroblast growth factor 23 (FGF23) was
undetectable, with C-terminal FGF23 fragments significantly elevated (2575 RU/ml, normal <180 RU/ml).
Sequencing demonstrated homozygous c.486C >A (p.N162K) mutation in FGF23 exon 3, confirming the
diagnoses of primary FGF23 deficiency, the first case to be reported from India.
Keywords: Continuous ambulatory peritoneal dialysis, familial hyperphosphatemic tumor calcinosis,
primary FGF23 deficiency, sevelamer, sudden vision loss
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Hyperphosphatemia in children is an unusual finding, especially in the absence of renal failure, and when
reported, it is generally due to vitamin D intoxication, tumor lysis syndrome which is transient and situation
specific; isolated hypoparathyroidism and pseudohypoparathyroidism are two other conditions to be
evaluated in such cases.
Familial hyperphosphatemic tumoral calcinosis (FHTC OMIM211900) is a rare autosomal recessive
disease,[1] although the exact prevalence rate is unknown.[2] Most reported pediatric cases (78%) have
been 2–13 years of age.[3] It is associated with disturbed mineral metabolism and hyperphosphatemia as a
prominent manifestation.[4] If untreated, this may lead to metastatic calcification around the major joints, in
soft tissues and arterial walls, which is a common sequaele. There have been around 200 cases of FHTC
since its first report by Duret in 1899.
We report a case of FHTC with normal renal function in a 8-year-old boy who presented with acute,
permanent loss of vision, multiple neurological manifestations which accumulated over a period.
CASe reporT
The first presentation was at 4 years of age with right lower motor neuron (LMN) facial paralysis. Later at 6
years, he had left facial palsy. There was no involvement of other cranial nerves. On both occasions, facial
palsy resolved spontaneously over 4–5 months.
At 7 years of age, he had an episode of the transient decrease in vision in both eyes lasting for 15 min,
associated with holocranial headache and bone pain in both lower limbs. He was evaluated for cerebral
ischemic event; however, no abnormality was detected on brain magnetic resonance imaging (MRI) with
diffusion-weighted imaging. After 2 months, he had a fracture of right elbow following a trivial fall. He also
developed mild, left-sided hemiplegia at 7 years 8 months of age, which resolved spontaneously.
By his 8  year, he experienced a sudden, painless loss of vision in the right eye, 25 days before the
ophthalmic consultation. This was the first consultation at our institute; we noted frontal bossing,
dolichocephaly, abnormal crowding of teeth, and a submental hard painless swelling.
There was only perception of light in the right eye during this visit. Vision in the left eye was normal;
whitish calcium-like deposits were present on the posterior border of the lid margins, the conjunctiva in the
interpalpebral zone of both eyes [Figure 1]. He had full ocular movements and right esotropia of 30 prism
diopters. There was a relative afferent pupillary defect of Grade 4 with optic atrophy in the right eye. Visual
evoked potential (VEP) showed extinguished flash response (EFR) on the right side. Flash VEP was normal
in the left eye. Optic nerve head appearance was normal on the left side [Figure 1].
Complete blood picture, serum sodium, potassium, chloride, renal function tests, and urinary pH were
within normal limits. Serum inorganic phosphorus was high (9.4 mg/dL) with normal alkaline phosphatase
(193 U/L) [Table 1]. Renal parameters were normal [Table 2]. Normal functioning of parathyroid glands
was denoted by normal PTH level and negative scintigraphy for adenoma. Persistent hyperphosphatemia
was documented on repeat evaluation [Table 2].
Brainstem auditory evoked response showed bilateral moderate hearing loss. X-rays of the long bone and
computed tomography (CT) brain with bone window demonstrated soft-tissue and vascular calcification.
X-ray of the knee, wrist, and spine showed sclerotic changes. Extensive sclerosis of skull vault, metastatic
calcification of the subcortical frontal lobe and basal ganglia, tentorium cerebelli, falx cerebri, submental
th
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region, and wall of the ophthalmic artery and carotid artery on both sides [Figure 2] were noted on
noncontrast CT of the brain and orbits.
We started him on the oral phosphate-binding agent (Sevelamer 800 mg three times a day [t.i.d]) at 8 years
of age the time he consulted us, which lowered the phosphate levels marginally but failed to bring it to the
normal range.
Five months after the loss of vision in the right eye, there was an acute painless visual loss in the left eye.
The left pupil showed a minimal reaction to the direct light. The fundus showed right-sided optic atrophy
and normal optic nerve on the left side. EFR was seen with VEP on the left side; however, flash VEP
showed a good response indicating retrobulbar pathology, possibly due to ischemia. Figure 3 depicts the
chronology of symptoms.
On both occasions of visual loss, he received intravenous methylprednisolone (500 mg/day in divided doses
for 3 days). Failing to control phosphate levels by oral therapy (sevelamer, 800 mg t.i.d) alone, he was
started on hemodialysis for 3 months and kept on maintenance therapy with a target to achieve serum
inorganic phosphorus <5.5 mg/dl and calcium phosphate <60 mg/dL. Other than dialysis to reduce
phosphate and sevelamer, we initially tried on aluminum hydroxide and low phosphate diet for 2 months,
but without any effect. Despite regular continuous ambulatory peritoneal dialysis (CAPD) for 3 years using
solutions with low phosphate, his serum phosphorus levels never normalized. Throughout his illness, urine
output was adequate with normal renal function.
He died of acute respiratory failure with features of septicemia at the age of 12 years. The child presented
acutely with fever, swelling of lower limbs, and breathing difficulty. His blood tests demonstrated elevated
white blood cell count with 82% polymorphs and elevated C-reactive protein (96 mg/dl). After starting
antibiotics, he deteriorated rapidly and succumbed. He did not have evidence of peritonitis, during this
period, calcium and phosphorus were similar to earlier observations. Although his immune status might
have been affected by his poor oral intake, and dietary restrictions, we could not find an immediate causal
relation to his death and FHTC. Persistent hyperphosphatemia with normal renal function and metastatic
calcification in this child suggested the diagnosis of familial tumoral calcinosis and he was further evaluated
biochemically and by DNA sequencing.
Intact FGF23 was undetectable (below 3 pg/ml), while the C-terminal FGF23 fragments were significantly
elevated (2575 RU/ml [normal <180 RU/ml]). Sequencing demonstrated no mutation in the GALNT3 gene,
but a homozygous c.486C>A mutation on FGF23 exon 3. This novel mutation results in the substitution of
asparagine to lysine (p.N162K). His parents were both heterozygous for this mutation.
dISCUSSIoN
Recent advances in genetics have identified FHTC as a monogenic disorder resulting in hyperphosphatemia
due to fibroblast growth factor 23 (FGF 23) deficiency,[5,6,7] while FHTC and hyperostosis-
hyperphosphatemia syndrome have been described as separate entities, and few reports indicate that these
entities are part of a continuous spectrum of the same disease.[8,9]
As a consequence of this derangement in phosphate metabolism, soft-tissue calcifications are frequent
which may appear like a mass (tumoral); hence, the name and clinical presentation vary depending on the
affected site. There are reports of skin and long bone involvement, corneal calcification, and angioid streaks
associated with FHTC. However, the combination of persistent hyperphosphatemia unresponsive to
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treatment, varied neurological presentations, and vision loss has not been reported.
The optic nerve sheath and the ophthalmic artery are the two possible sites of calcification around the optic
nerves. Concurrent carotid artery calcification makes ophthalmic artery involvement more likely.
Ophthalmic artery calcification with pipestem pattern without ischemic episodes has been reported in one
patient of diabetes mellitus with renal failure.[10]
Our patient consulted us at the age of 8 years for the sequential loss of vision in both eyes, initially in the
right eye, and later in the left eye. The presence of deposits on the lid margins, the conjunctiva of both eyes
indicated an abnormality in mineral metabolism. A history of bone pain in the past strengthened our
suspicion and LMN facial palsy was suggesting possible facial canal narrowing/ischemic pathology with
spontaneous improvement.
During the initial episode, a relative afferent pupillary defect of Grade 4 with optic atrophy, EFR on VEP in
the affected eye (right eye) indicated anterior visual pathway pathology. In general, it takes around 2–4
weeks to develop subtle optic disc pallor (partial optic atrophy).
In the second episode, where the left eye was involved, EFR on VEP was seen in the affected eye; flash
VEP showed a good response indicating a retrobulbar anterior visual pathway defect, possibly due to
ischemia.
He had intermittent headache during his course of illness, and never papilledema was noted during his
detailed ophthalmological evaluations done on a regular basis. Neither CT scan nor MRI brain revealed any
features of chronic raised intracranial pressure; there was no evidence of consecutive optic atrophy.
We noted persistent hyperphosphatemia, sclerosis of bone and soft-tissue metastatic calcification, which
further strengthened our diagnosis of TC. We noted patchy calcification surrounding the optic nerve in our
patient, which could have led to posterior ischemic optic neuropathy.
Undetectable intact FGF23 levels and a homozygous FGF23 mutation confirmed our diagnosis. FGF23
plays an important role in maintaining phosphate homeostasis, and inadequate intact FGF23 concentrations
result in hyperphosphatemia.
FGF23 is a potent regulator of serum phosphate concentrations by decreasing phosphate reabsorption in the
renal proximal tubule, leading to increased renal phosphate excretion. It also is an important regulator of
calcitriol by decreasing 1 α-hydroxylase (CYP27B1) and increasing 24 hydroxylases (CYP24A1) in the
proximal tubule. Thus, inactivating mutations of FGF23, as well as GALNT3 (which O-glycosylates
FGF23) or Klotho (a co-receptor for FGF23), gives rise to hyperphosphatemia and increased, or
inappropriately normal calcitriol concentrations.[11]
Our patient had a homozygous FGF23 mutation that resulted in failure to secrete full-length, biologically
active FGF23, leading to hyperphosphatemia, soft-tissue calcifications, and sclerotic bone. In addition, he
had unusual neurologic and ophthalmic manifestations. Although the longitudinal measurement of FGF23 is
unavailable, this unusually severe phenotype may suggest severe FGF23 deficiency.
Ophthalmic involvement, which is often associated with FHTC, manifests as calcifications of the eyelid,
cornea, and/or angioid streaks. Interestingly, calcium salts commonly deposit in the conjunctiva and cornea,
and rarely in the walls of the globe.[12,13]
Conjunctival calcification as seen in our case is the result of hyperphosphatemia and can be seen in patients
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with chronic renal failure. Increased pH of exposed palpebral aperture leads to precipitation of calcium
phosphate salts. It is almost always associated with corneal calcium deposition in varying degree, which
resembles Vogt's limbal girdle.[12] Our patient was asymptomatic for the ocular calcification and had
normal renal function. Calcification of eyelid margin noted in our patient is a rarer phenomenon and
reported only in a few cases of familial tumoral calcinosis.[14,15]
The cause of visual loss in this child is not clear. Narrowing of the optic canal though present, does not seem
to be the likely cause. Abrupt onset of visual loss on both occasions is not favoring compressive optic
neuropathy in which gradual decrease in visual acuity is the characteristic feature. Visual morbidity in
sclerotic bone diseases is attributable to compromised optic canals,[12] although retinal degeneration has
also been reported in some cases. With electroretinography being normal in our patient, sudden total loss of
optic nerve function is consistent with an ischemic event. The history of transient loss of vision and
spontaneously resolving seventh nerve palsy strongly support the possibility of an ischemic pathology.
Sudden vision loss has not been reported in the literature.
Primary FGF23 deficiency is associated with features of soft-tissue calcification as seen in the index case.
Persistent hyperphosphatemia, in this case, was recalcitrant to sevelamer, hemodialysis and CAPD.
Pharmacological therapy did not reduce the serum phosphate levels to the optimum level requiring
hemodialysis and CAPD to achieve the goal in the absence of renal failure. Although we could not achieve
reduction of the phosphate levels to the target (serum inorganic phosphorus <5.5 mg/dl and calcium
phosphate <60 mg/dL)) with CAPD, he survived for 3 years. He died prematurely at the age of 12 years due
to severe septicemia.
This is one of the most severe forms of FGF 23 mutation detected; no other reported cases in the literature
had visual loss and serial neurologic involvement with premature death.
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Figures and Tables
Figure 1
Image demonstrating chalky deposits on the posterior margin of the eyelid and fundus demonstrating optic atrophy in the
right eye
Table 1
Laboratory parameters
Laboratory Parameters Observation Normal range Remark
Venous blood pH 7.278 7.31-7.41 Low, but not significant
Serum inorganic phosphorous 9.4 mg/dL 3.1-5.9 mg/dL High
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Serum calcium 9.9 mg/dL 9-10.1mg/dL Within range
Parathormone 16pg/mL 12-95pg/mL Within range
S. Alkaline phosphatase 193U/L 218-499 U/L Low
Urinary Phosphate 53mg/dL 3.7-5.4 mg/dL High
Parameters Normal values Observations
First Second Third Fourth Fifth
Serum Calcium (mg/dL) 8.5-10.5 9.5 10.4 7.2
Serum Phosphorous (mg/dL) 3.8-6.5 8.1 9.4 7.8 9.2 9.6
Alkaline Phosphatase (IU/L) 208-450 145 106
Calcium (Spot urine) 9.9
53
Phosphorous (Spot urine) 12 32
Creatinine (Spot urine) 96 30 140
Parathormone (pg/mL) 12-95pg/mL 16
High serum phosphorous along with increased urinary phosphate in the presence of normal serum calcium &
parathormone levels. There was persistent hyperphosphatemia with normal renal parameters
Table 2
Constitution of dialysate
Parameter Concentration
Anhydrous Glucose* 1.36%w/v
Glucose monohydrate* 1.50%w/v
Sodium chloride* 0.538%w/v
Sodium lactate 0.448%w/v
Calcium chloride* 0.0184%w/v
Magnesium chloride* 0.0051%w/v
Parameter mmol/L
Sodium (Na ) 132.00
Calcium (Ca ) 1.25
Magnesium (Mg ) 0.25
Chloride (Cl ) 95.00
†
+
2+
2+
-
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Lactate (C H O ) 40.00
Osmolarity (mOsm/L) 344
p  at 25°C 5.5
*European Pharmacopea, French Pharmacopea
Figure 2
Computed tomography sagittal section of the brain (bone window) depicting calcified lymph nodes in the submental region
with calcification of falx and hyperdense cortex of the flat bones of the skull, and coronal section bone window
demonstrating patchy calcification of optic nerve, more prominent on the right side than left, along with areas of gyral
calcification on the left more than the right hemisphere
Figure 3
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Chronology of symptoms (supplementary)
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